IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
INTERPACE BIOSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$5.00−0.15 (-2.91%)
Close on Oct 19, 2026
- Market cap
- $138.57M
- P/E (TTM)
- 5.6
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
62.3%+29.2 pts over 5 years
Operating margin
10.5%+91.0 pts over 5 years
Net margin
63.5%+145.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -17.5% | +6.7% | +3.6% | +15.2% | |
| Gross profit | -19.4% | +9.8% | +17.6% | +25.3% | |
| Operating income | -49.6% | – | – | – | |
| Net income | +266.7% | – | – | – | |
| EPS, diluted | +122.5% | – | – | – | |
| Free cash flow | +45.2% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 100013.6% | 157.6% | 244.0% | |
| Return on assets | -49.0% | -54.4% | 101.1% | |
| Current ratio | 0.26 | 0.77 | 1.94 | |
| Debt to equity | -0.78 | -0.17 | – | |
| Net debt to EBITDA | -3.73× | -0.07× | – | |
| Interest coverage | -3.0× | -47.5× | – | |
| Inventory turnover | – | 11.2× | 12.6× | |
| Capex to revenue | – | 4.9% | 0.9% | |
| Diluted shares | 0M | 4M | 28M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Interpace Biosciences generated $30.68M from operations and spent $2.38M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$30.68M
Used
$2.38M
Capital expenditure$2.38M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin63.5%
×Asset turnover1.59×
×Equity multiplier2.41×
=Return on equity, FY2025244.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 63.5% | 1.59× | 2.41× | 244.0% |
| FY2024 | 14.3% | 3.36× | -0.48× | -23.2% |
| FY2023 | 4.9% | 2.75× | -0.26× | -3.4% |
| FY2022 | -69.0% | 1.17× | -0.54× | 43.7% |
| FY2021 | -182.3% | 0.19× | -1.18× | 41.8% |
| FY2020 | -81.6% | 0.67× | -2.90× | 157.6% |
| FY2019 | -110.4% | 0.59× | 7.54× | -487.6% |
| FY2018 | -58.0% | 0.65× | 1.77× | -66.3% |
| FY2017 | 79.0% | 0.51× | 4.83× | 196.4% |
| FY2016 | -168.2% | 0.29× | -2042.66× | 100013.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$24.58M
- Cash generatingOperating cash flow above zero$5.83M
- Return on assets improvedROA up on the prior year51.1% → 166.1%
- Earnings backed by cashOperating cash flow above net income$5.83M vs $24.58M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.11 → 1.94
- No dilutionShare count did not rise16M → 28M
- Gross margin improvedGross margin up on the prior year63.77% → 62.31%
- More efficientAsset turnover rose3.58 → 2.62